The objective of this study is to estimate the costs of empiric antibiotic therapy and hospitalization costs for patients with a complicated intra-abdominal infection, and to assess the impact of treatment failure of initial antibiotic empiric therapy on pharmacological and total healthcare costs for these patients in Greece.
Every patient diagnosed with complicated intra-abdominal infections will enter the study, until the pre-specified number of patients is reached. Patients diagnosed with any of conditions mentioned below (inclusion criteria) will enter the study, until the pre-specified number of patients is reached.
Study Type
OBSERVATIONAL
Enrollment
203
success of the initial empiric treatment
Pfizer Investigational Site
Athens, Athens, Greece
Pfizer Investigational Site
Athens, Athens, Greece
Pfizer Investigational Site
Cholargós, Athens, Greece
Duration of Hospitalization
Overall health care resource utilization was analyzed using mean duration of hospitalization.
Time frame: Baseline up to 6 months
Percentage of Participants With Initial Empiric Antibiotic Therapy (by Therapeutic Class)
Time frame: Baseline up to 6 months
Percentage of Participants With Failure of Initial Empiric Antibiotic Therapy
Failure of initial empiric therapy was assessed by an independent committee of qualified healthcare professionals (surgeon, and microbiologist specialist) and defined as requirement of additional antibiotic or change in antibacterial therapy on any day following the initial laparotomy, laparoscopy, or percutaneous drainage; or additional laparotomy, laparoscopy, or percutaneous drainage at least 2 days following the initial surgical/radiological intervention; or participant death due to infection.
Time frame: Baseline up to 6 months
Duration of Hospitalization (by Failure of Initial Empiric Treatment)
Yes equals (=) initial empiric antibiotic treatment failed (additional antibiotic therapy or a change in antibacterial therapy was required following laparotomy/laparoscopy or percutaneous draininge or participant died due to infection); No=initial empiric antibiotic treatment successful (infectious process resolved and no change in initial empiric antibiotic therapy was required during the course of hospitalization except for stepdown therapy, de-escalation or intravenous to oral switch).
Time frame: Baseline up to 6 months
Percentage of Participants With Specific Pathogen
Time frame: Baseline up to 6 months
Percentage of Participants by Diagnosis at Discharge
Time frame: Month 6 or study exit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Haidari, Athens, Greece
Pfizer Investigational Site
Marousi, Athens, Greece
Pfizer Investigational Site
N. Ionia, Athens, Greece
Pfizer Investigational Site
Peireus, Athens, Greece
Pfizer Investigational Site
Rio, Patras, Greece
Pfizer Investigational Site
Thessaloniki, Thessaloniki, Greece
Pfizer Investigational Site
Thessaloniki, Thessaloniki, Greece
...and 3 more locations